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Abstract: Aberrant methylation of multiple promoter CpG islands could be related to the
biology of ovarian tumors and its determination could help to improve treatment strategies.
DNA methylation profiling was performed using the Methylation Ligation-dependent Macroarray
(MLM), an array-based analysis. Promoter regions of 41 genes were analyzed in 102 ovarian tumors
and 17 normal ovarian samples. An average of 29% of hypermethylated promoter genes was
observed in normal ovarian tissues. This percentage increased slightly in serous, endometrioid,
and mucinous carcinomas (32%, 34%, and 45%, respectively), but decreased in germ cell tumors
(20%). Ovarian tumors had methylation profiles that were more heterogeneous than other epithelial
cancers. Unsupervised hierarchical clustering identified four groups that are very close to the
histological subtypes of ovarian tumors. Aberrant methylation of three genes (BRCA1, MGMT,
and MLH1), playing important roles in the different DNA repair mechanisms, were dependent on the
tumor subtype and represent powerful biomarkers for precision therapy. Furthermore, a promising
relationship between hypermethylation of MGMT, OSMR, ESR1, and FOXL2 and overall survival was
observed. Our study of DNA methylation profiling indicates that the different histotypes of ovarian
cancer should be treated as separate diseases both clinically and in research for the development of
targeted therapies.
Keywords: ovarian carcinoma; DNA methylation profiling; Wnt pathway; DNA damage repair
system; TERT; MGMT; BRCA1; MLH1; OSMR; ESR1; FOXL2
1. Introduction
Ovarian cancer is the sixth most common cancer in women worldwide but has the highest
mortality rate among gynecologic cancers. More than 90% of ovarian cancers are malignant surface
epithelial tumors (carcinomas) and arise from relatively pluripotent cells of the surface epithelium,
the coelomic epithelium, or “modified mesothelium” [1,2]. There is now compelling evidence that some
carcinomas can also originate from the fallopian tubes and the endometriosis [3]. Ovarian carcinoma
is an extremely aggressive disease and only a few cancers are diagnosed at early stages due to the
absence of symptoms. In the majority of patients, the disease was characterized by rapid spread
into the pelvis and the peritoneal cavity with poor prognosis. Despite the combined surgery and
chemotherapy, recurrences are frequent with a low five-year survival rate [4,5].
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Ovarian carcinoma is a heterogeneous disease with differences in tumor morphology, clinical
evolution, and genetics. The main histological subtypes are serous, mucinous, and endometrioid for
their resemblance to the tissues of the female genital tract.
However, some issues about ovarian cancers are still unclear: the origin of most of the ovarian
carcinomas is controversial, the rate of relapse is surprisingly high, and its cause is unknown. Therefore,
there is an urgent need to better understand the biology of the ovarian cancer in order to improve the
diagnosis and to adapt the treatment according to the characteristics of the tumor.
To date, several oncogenes or putative tumor suppressor genes have been implicated in ovarian
carcinogenesis [6]. The most commonly activated oncogenes by point mutation are KRAS, BRAF, and
PIK3CA. Among the tumor suppressor genes, TP53, PTEN, BRCA1, and BRCA2 are frequently lost or
inactivated in epithelial ovarian cancer (EOC). Moreover, several signaling pathways are commonly
activated in ovarian carcinomas, including the EGFR, the Ras/MAPK, the PI3K/AKT, the IL6/STAT3,
the NF-κB, and the hedgehog pathways [7,8].
Epigenetic mechanisms also contribute to the inactivation or downregulation of tumor suppressor
genes. Several tumor suppressor genes, including CDH1, CDKN2A, DAK1, DLEC1, MLH1, and
RASSF1A, were found to be downregulated by promoter methylation in ovarian cancer [9]. Furthermore,
BRCA1 (breast cancer type 1 susceptibility gene) was found to be inactivated by promoter methylation
as well as by mutation and loss of heterozigosity (LOH) [10,11].
DNA methylation profiles among different types of ovarian cancer indicate that significantly
fewer hypermethylated genes are present in high-grade serous carcinomas than in low-grade serous
carcinoma and borderline tumors [12]. Various DNA hypermethylation patterns were also identified in
different ovarian cancer subtypes, thus suggesting that the cancer origin may involve different biology
through different epigenetic mechanisms [13].
In this paper, we analyze the DNA methylation status of a large subset of genes to evaluate if
epigenetic alterations can be related to the biological onset of these neoplasias. These putative cancer
biomarkers may help to identify relevant biological aspects of ovarian cancer. We used a new approach,
Methylation Ligation-dependent Macroarray (MLM) (recently published by Guilleret et al. [14]),
to allow the analysis to be more rapid, specific, and efficient, thereby allowing screening of many
promoter genes in many samples at the same time.
2. Results
The analysis of DNA methylation profiling of 41 promoter regions using the new MLM
technology [14] was performed on 102 ovarian tumors and 17 normal control tissues (Figure 1).
The level of methylation was considered low for β-value < 0.3 (white color), partial or intermediate
for β-value ≥ 0.3 and ≤ 0.7 (grey color), and high for β-value > 0.7 (black color). A promoter region
was considered hypomethylated when the β-value was less than 0.3. This value was chosen because
our microdissection guaranteed a percentage of tumor cells greater than 70% and thus a methylation
up to 30% could originate from the non-tumor cells. The average number of hypermethylated genes
varied depending on the histologic tumor subtypes. For the 17 normal control cases, an average of 29%
(11.8/41 genes) of hypermethylated genes was observed. This average percentage increased slightly
in the serous (32%; 13.1/41 genes) and endometrioid (34%; 14.1/41 genes) carcinomas, and more
significantly in the mucinous (45%; 18.4/41 genes) carcinomas. On the other hand, a decrease in the
number of hypermethylated genes was observed in the germ cell tumors (20%; 8.1/41 genes).
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Figure 1. Methylation profiling by MLM in ovarian tumors. Methylation profiling of 41 gene 
promoters was performed in 17 normal ovarian tissues, and in 102 microdissected ovarian tumor 
tissues. Each row represents a gene and each column a tissue sample. Black boxes indicate high 
methylation (β-value > 0.7), grey boxes intermediate or partial methylation (β-value ≥ 0.3 and ≤ 0.7) 
and white boxes low methylation (β-value < 0.3). 
Figure 1. Methylation profiling by MLM in ovarian tumors. Methylation profiling of 41 gene
promoters was performed in 17 normal ovarian tissues, and in 102 microdissected ovarian tumor
tissues. Each row represents a gene and each column a tissue sample. Black boxes indicate high
methylation (β-value > 0.7), grey boxes intermediate or partial methylation (β-value ≥ 0.3 and ≤ 0.7)
and white boxes low methylation (β-value < 0.3).
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Manual microdissection has been performed on formalin-fixed, paraffin-embedded (FFPE) tissues
to reach a minimum of 70% of tumor cells. Therefore, a hypo- or a hyper-methylation should be
observed for most of the promoter genes in the tumor tissues. However, for almost all the tumors and
for most of hypermethylated genes, an intermediate or partial level of methylation (β-value ≥ 0.3 and
≤ 0.7) was noticed (grey color in Figure 1), which could indicate a high level of intratumor heterogeneity
in ovarian tumors.
Unsupervised hierarchical clustering identified mainly three clusters of tumors (Figure 2).
The Cluster 1 corresponds to the tumors with the greatest number of hypermethylated genes.
All but one of the tumors of this group were mucinous carcinomas. Moreover, more than half of the
mucinous carcinomas (53%; 16/30 samples) were contained in this cluster.
The Cluster 2 included almost all the endometrioid carcinomas (83%; 25/30). In addition,
few serous and mucinous carcinomas (seven cases for each group) were also present in this cluster.
The Cluster 3 corresponds to the tumors with the lowest number of hypermethylated genes.
These cluster included all normal ovarian tissues, all germ cell tumors, and the majority of serous
carcinomas (74%; 26/35 samples). In addition, few mucinous and endometrioid carcinomas (6 and
4 cases, respectively) were also present in this cluster. The Cluster 3 can be divided in two groups,
3A and 3B. The Group 3A contained all but one of the non-tumoral tissues. The Group 3B contained
all the germ cell tumors and the majority of the serous carcinomas (63%; 22/35 samples). The presence
of normal tissues and germ cell tumors could alter the clustering of epithelial tumors. To exclude this
possibility, a clustering including only the epithelial tumors was performed. Three clusters were once
more obtained, with the majority of mucinous carcinomas in the first one, the majority of endometrioid
carcinomas in the second one, and more than two-thirds of serous carcinomas in the third cluster
(Figure S1).
Some promoter genes—ADAMTS12, MGMT, SPARC, TAC1, and TERT—were hypomethylated
in most normal tissues (Figure 1 and Group A in Figure 2) and were hypermethylated in a majority
of tumors. However, this change in methylation level was not uniform and, for some genes, it will
be different according to the tumor type. ADAMTS12 and MGMT were hypermethylated in almost
all of the endometrioid, mucinous, and germ cell tumors. On the other hand, in serous carcinomas,
only 51% and 31% of the tumors were found hypermethylated for ADAMTS12 and MGMT, respectively.
For the TERT gene, the number of hypermethylated tumors was dependent on the histological type.
The endometrioid carcinomas were very often TERT hypermethylated whereas the opposite occurred
in germ cell tumors, respectively, 83% and 11%. TERT methylation was observed in 71% of serous and
50% of mucinous carcinomas.
In normal tissues, several genes—DAX1, ESR1, FBP1, and SOCS3—showed an intermediate
methylation level in more than three-quarters of samples. The case of DAX1 is particularly interesting.
With the exception of germ cell tumors, where hypomethylation is observed in all but one case,
a majority of mucinous and serous carcinomas showed a strong hypermethylation of DAX1 (black boxes
in Figure 1).
There are six genes (MAL, MYOD1, OSMR, SEPTIN9, SFRP1, and SFRP4) for which
hypermethylation is observed almost exclusively or preferentially in mucinous carcinomas (Figure 1).
Moreover, for each of these genes, at least two-thirds of tumors with hypermethylation were present
in cluster 1 (Figure 2). With the exception of APC, a hypermethylation of the genes belonging to the
Wnt/β-catenin signaling pathway—DKK2, SFRP1, SFRP4, SFRP5, and WIF1—appeared mainly in the
clusters 1 and 2. All these observations are confirmed by the analysis with the Student’s t test with
unequal variances at p < 0.05.
The MLM analysis revealed that some genes—such as ADAMTS1, CDNK2A (p16), PTGS2, SMAD4,
WNT4, and WRN—were never or uncommonly found hypermethylated in our series of tumors and
normal ovarian tissues.
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Figure 2. Hierarchical clustering of 41 differentially methylated gene promoters in 102 ovarian tumors 
and 17 normal ovarian tissues. The methylation levels (M-values) vary from 0 (0% methylation, green) 
to 1 (100% methylation, red). Cluster 1 (cyan); Cluster 2 (yellow); and Cluster 3 (pink, with groups A 
and B). 
The survival analysis was possible for 86 of the 95 patients with ovarian carcinoma. For nine 
cases, two endometrioid, three serous, and four mucinous, the data were not available. The five-year 
overall survival revealed that the median overall survival times was 47 months for serous carcinomas, 
44 months for the mucinous carcinomas, and 56 months for the endometrioid carcinomas. Fifteen 
patients died of the disease for serous carcinoma (all but three were at stage 3), ten for mucinous 
carcinoma (stage 3 was observed in four cases, 2 in one, and 1 in five cases), and three for 
endometrioid carcinoma (one at stage 1, one at stage 2, and one at stage 3). Recurrence was observed 
in nine cases of serous carcinoma (range 8–48 months), in one mucinous carcinoma (at 13 months), 
and in one endometrioid carcinoma (at 12 months). Our cohort is not completely representative for 
EOC due to the relatively low number of serous carcinomas that are the most frequent in the general 
population and are usually most advanced cancers. The statistical survival analysis showed 
interesting results. Among all the patients with ovarian carcinomas harboring a methylation of OSMR 
or ESR1, β-value > 0.3 and M-value > −1.222, we found more patients dead of the disease than in the 
Figure 2. Hierarchical clustering of 41 differentially methylated gene promoters in 102 ovarian tumors
and 17 normal ovarian tissues. The methylation levels (M-values) vary from 0 (0% methylation, green)
to 1 (100% methylation, red). Cluster 1 (cyan); Cluster 2 (yellow); and Cluster 3 (pink, with groups
A and B).
The survival analysis was possible for 86 of the 95 patients with ovarian carcinoma. For nine cases,
two endometrioid, three serous, and four mucinous, the data were not available. The five-year
overall survival revealed that the median overall survival times was 47 months for serous
carcinomas, 44 months for the mucinous carcino as, and 56 months for the endometrioid carcinomas.
Fifteen patients died of the disease for ser s carcinoma (all but three were at stage 3), ten for mucinous
carcinoma (stage 3 was observed in four cas s, 2 in one, a 1 in five cas s), and thr e for end m trioid
carci om (one at stage 1, one t stage 2, and e at stage 3). Recurrence was observed i nine
cases of serous carcin ma (range 8–48 months), in one mucinou carcinoma (at 13 months), and in
one endometrioid carcinoma (at 12 m nths). Our ohort is not completely representative for EOC
due to he relatively low number of serous carci omas t at are the most frequent in the general
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population and are usually most advanced cancers. The statistical survival analysis showed interesting
results. Among all the patients with ovarian carcinomas harboring a methylation of OSMR or ESR1,
β-value > 0.3 and M-value > −1.222, we found more patients dead of the disease than in the cases
with a hypomethylation of these genes (p < 0.05). Moreover, a statistically significant difference in
mean overall-survival between patients with carcinomas harboring high methylation levels of OSMR
(β value > 0.7 and M-value > 1.222) compared to patients with carcinomas less methylated (12.5 vs.
25.0 months) was observed (p < 0.05). For two genes, RASSF1 and FOXL2, the patients who died of the
ovarian carcinoma showed a statistically higher mean of methylation compared to the patients who
were still alive (M-value of 6.63 vs. 4.16 for FOXL2 and 6.43 vs. 5.17, for RASSF1; p < 0.05).
The Kaplan-Meier method (R package “survival”, CRAN) was applied to widen the analysis
procedure (used function: survfit).
The overall survival curves were generated analyzing the survival behavior as a function of
two methylation levels, under and over a β-level threshold. The Log rank test was used to test the
significance of the difference between the two curves (used function: survdiff).
The curves for OSMR were obtained with two threshold levels, 0.3 and 0.7. In Figure 3a, the curves
show the threshold 0.3. Patients with unmethylated carcinoma (β-value < 0.3, blue curve) show a better
overall survival (Log rank p-value = 0.00042). The aspect of “shorter survival for larger methylation”
is reinforced by the results obtained with the threshold of β-value = 0.7. The corresponding survival
curves are reported in Figure 3b where the gap between them is much larger if compared to that for
lower threshold (Log rank p-value = 0.0013).
We had similar results for the curves related to ESR1, reported in Figure 3c, where they appear
well separated (Log rank p value = 0.0059).
An opposite behavior of the overall survival curves was found for MGMT gene, probably due to
its different association in specific histotypes of ovarian carcinoma. High methylation of MGMT seems
to favorite a higher survival probability, as shown in Figure 3d, where the reversed blue and red curves
look well separated (Log rank p value = 0.0019). We improved the survival analysis by stratifying the
samples for their histology and comparing the difference of survival curves between the histotypes by
Log rank test. The survival curves for OSMR, ESR1, and MGMT showed a similar feature (Figure 4).
A link between hypermethylation and survival was observed for serous and mucinous carcinomas only
(Figure 4a,b,d,e,g,h). For endometrioid histotype only one patient presented high methylation. OSMR
and ESR1 hypermethylation were associated with worse survival, whereas MGMT hypermethylation
provided better survival. Due to the limited number of samples in the different subgroups, statistical
significance was reached only for OSMR in serous carcinomas.
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Each graph legend reports the β threshold and their colors (red, blue) and the p value of the test for 
the significant difference between the curves. Curves for OSMR gene were generated with two 
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cases are marked by “+”. 
Figure 3. Kaplan-Meier analysis of overall survival of epithelial ovarian cancer patients. The analysis
was carried out through the function “survfit” of the R package “survival” (ver. 2.42-3, Available
online: https://cran.r-project.org/web/packages/survival/index.html) with the log-log mode setting.
Each graph legend reports the β threshold and their colors (red, blue) and the p value of the test for the
significant difference between the curves. Curves for OSMR gene were generated with two threshold
levels of β methylation, 0.3 and 0.7 (a,b), respectively. Curves for ESR1 gene were generated with
threshold 0.3 (c). The curves for MGMT gene were generated with threshold of 0.7 (d). The number of
patients in each subgroup is reported in the table at the bottom of each graph. The censored cases are
marked by “+”.
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S (Serous), M (Mucinous), E (Endometrioid). Curves were generated for OSMR (upp r panel) (a–c),
ESR1 (central panel) (d–f), and MGMT (lowest panel) (g–i). In each graph, the β threshold and their
colors (red, blue) and the p value are reported. Th umber of p tients in each subgroup is reported in
the table at the bottom of each graph. The censored cases are marked by “+”.
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3. Discussion
Aberrant methylation of multiple promoter CpG islands is a common event in human cancers and
is frequently observed in ovarian carcinomas [15]. It has thus been suggested that DNA methylation
changes may have implications for ovarian cancer diagnosis, prognosis, and treatment [16,17].
However, it is currently difficult to compare the results obtained from several previous studies for DNA
methylation analysis due to the different methods of analysis, the quantity of genes studied, and the
histological types investigated. In our study, using a new technique, Methylation Ligation-dependent
Macroarray (MLM) (recently published by Guilleret et al. [14]), we focused our analysis on the three
major types of epithelial carcinomas and on a large set of genes involved in several pathways, with the
aim of better understanding the biological onset of this neoplasia.
There are three major results that can be drawn from this study regarding the methylation profiles
of ovarian cancers.
Firstly, the profiles of methylation are quite heterogeneous, but clustering showed, however, that,
at the epigenetic level, there are different groups of tumors. The most interesting point is that these
groups reclassified by clustering are very close to the histological classifications. This observation has
been reported in previous studies [13,18–26] in which a small number of cases or a small number of
genes have been considered. Our work highlights and confirms the link between methylation and
histotypes due to relatively high number of cases analyzed (95 ovarian carcinomas and 7 germ
cell tumors) and to the selection of several genes involved in the carcinogenesis and ovarian
development. The connection between DNA methylation profiles and histological subtypes is
suggestive of various tumorigenic mechanisms and cells of origin and underlines the need to consider
the different histological ovarian carcinomas as different diseases. Treatment strategies require a better
understanding of the biology of each histological type.
In addition, our study also seems to confirm that none of the histological subtypes analyzed have
their origin in the majority of cells that make up the ovary.
Secondly, an intermediate level of methylation (about 50%) was observed for most hypermethylated
genes. Normally, either a high or a low level of methylation should have been observed because the
proportion of tumor cells in our samples was greater than 70%. This observation had already been
made for analyses of methylation on a single gene by our group but also by others [27,28]. However,
our study of 41 genes indicates that this phenomenon is quite general. This observation could mean
that some intratumoral heterogeneity exists for these various epigenetic alterations. Of course, it is also
possible that, for some genes, a methylation of a single allele occurs; in this case, gene expression by
the non-methylated allele is possible and therefore this monoallelic methylation does not lead to a stop
of expression.
Thirdly, in our series of ovarian tumors, the number of hypermethylated promoter genes is
relatively low for tumors that are considered epithelial. This observation particularly involves serous
and endometrioid carcinomas. Using the same MLM methodology, the number of hypermethylated
genes was found to be significantly higher in esophagus adenocarcinomas [14]. TERT (human
telomerase reverse transcriptase) transcription, which leads to telomerase activity, is one of the most
important factors linked to proliferation, differentiation, and senescence, and it is not found in the
majority of somatic cells. On the contrary, in the proliferative cells such as germ cells, stem cells,
and in the 80–95% of the tumors, TERT is expressed, which leads to telomerase activation [29,30].
Our previous studies on the regulation of the TERT gene showed that the promoter of this gene is
hypermethylated in 80–90% of epithelial tumors [31–33]. As expected, TERT was not methylated in
our series of non-epithelial germ cell tumors; on the other hand, TERT is hypermethylated in 83% of
endometrioid carcinomas but in only 71% of serous and 50% of mucinous carcinomas.
An important observation, which could have strong therapeutic implications, is the aberrant
promoter methylation of three genes (BRCA1, MGMT, and MLH1) playing important roles in the
different DNA repair mechanisms [34]. Unrepaired DNA damage by the DNA damage repair (DDR)
system is a major cause of mutagenic lesions. In human cancer, DNA methylation occurs more
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frequently than gene mutation in DDR genes [35]. As such, DNA methylation could play more
important roles in DNA damage repair genes during the development of cancer. Interestingly, aberrant
DNA methylation of DDR genes is a powerful biomarker for precision therapy in cancer [35].
Platinum agents and Poly(ADP-ribose) polymerase (PARP) inhibitors, a promising novel therapy,
are the most successful anticancer reagents in BRCA-deficient cancer cells [36]. BRCA1 and BRCA2
germline mutations are the most frequently responsible for hereditary breast and ovarian cancer.
Besides mutation, hypermethylation of the promoter of BRCA1, which is observed in
approximately 10–15% of sporadic ovarian carcinomas, and more especially in serous carcinomas,
could also predict response to PARP inhibitors [37]. There are actually very few clinical studies on
the role of BRCA1 methylation in the response to PARP inhibitors (PARPi), both in breast and ovarian
cancers. Many papers discuss the strong potential of this marker for PARPi response, but clinical
studies are still too few. A recent review article [37] discusses the results of clinical trials and the relation
between BRCA1/2 and PARPi in serous ovarian carcinomas. Apparently the long-term response is
much more pronounced for mutated tumors than for hypermethylated tumors. Using MLM, BRCA1
was found hypermethylated in 14% (5/35) of our series of serous tumors.
Defective mismatch repair (MMR) increases mutation rates and leads to microsatellite instability
(MSI), resulting in carcinogenesis. In epithelial ovarian cancer, microsatellite instability (MSI) was
observed in 14.9% of cases in a series of 834 samples [38]. MSI can be due to germline mutation
within at least one of four mismatch repair genes (MLH1, MSH2, MSH6, and PMS2), but more likely
to hypermethylation of the MLH1 promoter in sporadic cancers, including ovarian cancers, with an
occurrence of 37.5% [39]. With the exception of germ cell tumors, hypermethylation of MLH1 was
observed in more than half of our series of ovarian epithelial tumors. This result is in agreement
with the few data from the literature, in which there is apparently no correlation between MLH1
methylation and the histological subtype [40]. However, it may also be noted that normal ovarian
tissue also exhibited a partial methylation of MLH1 in 76% (14/17) of the analyzed cases. Promoter
methylation inhibits transcription when both alleles are methylated. It is therefore possible that
the observed methylation in some of the tumors comes either from the normal tissue or from the
methylation of a single MLH1 allele in the tumor cells, which in both cases does not lead to an inhibition
of MLH1 in the tumor. In our series, a complete methylation of MLH1 was observed for 11 cases,
where silencing of MLH1 expression can therefore be strongly suspected. Immunotherapy has shown
promising results in various types of cancers, including those with microsatellite instability-high
(MSI-H) or MMR-deficiency [41]. Further studies seem necessary to better understand the effect of
MLH1 methylation in ovarian cancers.
Aberrant hypermethylation of MGMT (O-6-Methylguanine-DNA Methyl Transferase) is
particularly interesting. This gene is involved in the repair of DNA damages and hypermethylation
is observed in several neoplastic and preneoplastic conditions [35,42] Recently, a meta-analysis that
evaluated the samples of 10 ovarian cancer studies showed the importance of MGMT methylation
in ovarian cancers [26]. Our study confirms the high occurrence of MGMT methylation in ovarian
cancers. We observed that complete methylation of MGMT was present in endometrioid (60%, 18/30),
mucinous (33%, 10/30), and germ cell (86%, 6/7) subtypes, but almost absent in serous carcinoma
(3%, 1/35). MGMT promoter methylation was significantly correlated with pathological types, and it
was significantly lower in serous carcinomas than in non-serous carcinomas. The association of MGMT
methylation with certain histological types was previously observed. This hypermethylation was
described as common in most histological subtypes, with the exception of serous carcinoma [43,44],
as shown in our study. Our data on survival analyses showed that MGMT hypermethylation leads
to a higher survival rate. This could be due to its role in DNA repair and thus, a better response
to chemotherapy, as observed in glioblastoma [45] but also in advanced ovarian cancer [46]. In our
cases, the link between hypermethylation and better survival was found particularly for serous and
mucinous histotypes. Further studies conducted on large series of carcinomas, and more importantly
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with distinction of the different histotypes, are required to determine the precise role of MGMT
methylation in ovarian tumorigenesis and outcome.
Aberrant activation of the Wnt/β-catenin pathway plays an important role in a wide variety
of cancers [47]. This activation occurs throughout genetic or epigenetic alterations of intracellular
or extracellular components of this pathway. Wnt activation has been observed in several cancer
types, including colorectal carcinoma, pancreatic adenocarcinoma, leukemia, melanoma, but also in
ovarian carcinoma [48]. In our series, hypermethylation of the Wnt antagonists (DKK1, DKK2, SFRP1,
SFRP4, SFRP5, and WIF1) were observed with a significant prevalence in mucinous and endometrioid
carcinomas. Promoter methylation of SFRP4 and SFRP5 has been associated with advanced stage
of the disease and resistance to chemotherapy [11,49]. Given the critical roles of the Wnt/β-catenin
pathway in many cancers, substantial efforts have made to develop therapeutic approaches to target
this pathway, which could be useful for treating ovarian cancer.
Hypermethylation of FOXL2 (Forhead box L2), ESR1 (Estrogen Receptor 1), and OSMR
(Oncostatin M receptor) was rather indicative of poorer overall survival and could be used as a
biomarker of prognosis. Interestingly, for OSMR and ESR1 the link between hypermethylation and
worse survival was especially noted for serous and mucinous histotypes in our study. These data
are promising, but detailed studies on a more number of patients are needed. It is interesting to note
that these three genes play a role in ovarian cells. The transcription faction FOXL2 (Forhead box
L2) has a key role in all stages of ovarian development and maintenance, and regulates apoptosis,
proliferation, and differentiation of follicular cells [50]. ESR1 is involved in sexual development and
OSMR (oncostatin M receptor), a cell surface receptor, has a possible role with OSM in growth initiation
of primordial follicles [51]. At least for one of these three genes (ESR1), an inverse correlation between
methylation and survival has previously been observed [52].
In conclusion, our study highlighted the large heterogeneity of DNA methylation profiles in
ovarian cancers. Nevertheless, clustering identified four groups significantly associated with the
known ovarian cancer histological subtypes. This observation supports the need to treat the different
histologies of epithelial ovarian cancer as different diseases, both clinically and in research for the
development of targeted therapies. The differentially methylated genes we have identified or confirmed
in this study may provide clues into the biological characteristics of the different cancer subtypes.
Taking into account the high potential of epigenetic biomarkers, further research may lead to successful
new drug targets for the development of subtype-specific therapies for ovarian cancer.
4. Materials and Methods
4.1. Patients and Tissues
The study was conducted on ovarian tissues obtained from women surgically treated for
an ovarian carcinoma without preoperative chemotherapy. The Ethics Committee of Azienda
Ospedaliero-Universitaria di Modena (project identification code 167/16) approved the study on
20 July 2016. The samples were collected at the Unit of Pathology of Modena between 1995 and
2005 and included 35 serous carcinomas, 30 mucinous carcinomas, and 30 endometrioid carcinomas.
Seven germ cell tumors (six dysgerminoma and one embryonal carcinoma) were added to the study.
The patients with mucinous carcinomas were carefully evaluated in search of a primary mucinous
carcinoma at another site. We excluded the cases with positive immunostaining for CDX2, CEA,
or CK20 (more specific for intestinal origin) or negative for CA125. Table 1 reports the clinical and
pathological features of patients with ovarian tumors.
The stage was established according to the International Federation of Gynecology and Obstetrics
(FIGO) criteria [53]. The pathological grade was specified by the Silverberg grading system
(grades I–III) [54] and for serous tumors in low and high-grade according to the recently proposed
two-tier grading system [55].
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Table 1. Clinical and pathological features of patients with ovarian tumors.
Neoplasia Number Mean Age Grade Stage
Serous carcinoma 35
58 Low grade: 5
High grade: 30
I = 11
II = 4
Min = 37 III = 19
Max = 87 IV = 1
Mucinous carcinoma 30
59 I = 15 I = 24
Min = 30 II = 8 II = 3
Max = 85 III = 7 III = 3
Endometrioid carcinoma 30
60 I = 14 I = 22
Min = 36 II = 9 II = 5
Max = 88 III = 7 III =3
Germ cell tumor 7
25
-
I = 6
Min = 12
II = 1Max = 33
For control cases, we selected 17 normal ovarian tissues from women without cancer who has
surgery for benign gynecological conditions (mean age of 58 years). Tissues were formalin fixed,
paraffin embedded, and cut to obtain sections of 3–4 µm. After staining with hematoxylin and eosin,
the sections were observed by pathologists in order to confirm the histopathological diagnosis.
4.2. Microdissection and DNA Extraction
The sections were deparaffinized, rinsed and stained in 0.1% toluidine blue for 30 s, washed, air
dried, and stored before microdissection. This microdissection was made manually using a scalpel
blade under microscopic control to remove a majority of the non-neoplastic tissue, such as immune
cells or necrosis, in order to enrich the samples to at least 70% of tumor cells. The pathologist (LL)
confirmed the accuracy of this procedure before the collection of the enriched tumor samples. DNA was
extracted using the Promega Maxwell 16 FFPE Plus LEV DNA Purification Kit (Promega, Madison, WI,
USA) following manufacturer’s instructions. DNA quantification was performed using standardized
PicoGreen fluorescence assay (Invitrogen, Carlsbad, CA, USA).
4.3. Methylation by Methylation Ligation-Dependent Macroarray (MLM)
To analyze many promoter genes in many samples at the same time, a methylation macroarray
has been developed. A homemade methylation macroarray, termed Methylation Ligation-dependent
Macroarray (MLM), has been generated using promoters known to undergo methylation changes in
cancers. The method consists of five steps, as previously reported [14].
The methylation level was expressed by the β-values, which were calculated as follows:
β = (intensity value in assay tube/intensity in control tube) divided by the mean β value obtained
for the restriction site free targets. Finally, β ≤ 0 were replaced by 0.01 while β ≥ 1 were replaced
by 0.99. The level of methylation was considered low for β-value < 0.3, partial or intermediate for
β-value ≥ 0.3 and ≤ 0.7, and high for β-value > 0.7.
4.4. DNA Methylation Unsupervised Hierarchical Clustering and Statistical Analysis
After data conversion from β-values to M-values in which M= log2 {β/(1-β)} , the M-values were
first submitted to exploratory analysis of the methylation expression and, after statistical survival
analysis, to hierarchical clustering by means of the program R and Bioconductor software and package
survival (R Bioconductor package Heatplus v2.18.0 by Alexander Ploner, 2014) [56]. The exploratory
analysis was carried out by generating boxplots for every kind of each patient’s condition and ordering
them as a function of median M-values.
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The clusters associated to heatmap were generated with Euclidean distance between M-values
and complete distance between clusters. The cut thresholds for patients and gene clusters were
40.0 and 2.0, respectively.
4.5. Genes Investigated
The 41 promoter genes investigated are genes that are known to be able to be regulated by a
methylation change of their promoters. Among them, we selected some genes known to be altered
by DNA methylation in ovarian cancers (APC, ESR, MGMT, RASSF1A, MLH1, TERT, WT1), genes
implicated in testis and/or ovarian cells (BORIS/CTCFL, DAX1, FOXL2, RSPOI, TMEFF2), genes
involved in the Wnt pathway (APC, DKK1, DKK2, DKK3, SFRP1, SFRP4, SFRP5, WIF1, WNT4),
and genes implicated in repair pathways (BRCA1, MGMT, and MLH1).
4.6. Survival Analysis
Patients were followed-up according to the standard protocol every 6 months for 5 years. Optimal
debulking surgery was received in all but six patients (four serous carcinomas and two mucinous
carcinomas). Platinum-based chemotherapy treatment was applied for all patients at advanced stages
(3 and 4) and to 24 patients at stage 1C and 2.
Overall survival, defined as the period from surgery to the date of death associated to the disease,
and disease-free survival, defined as the time from the date of primary treatment to the date of
confirmed recurrence, were evaluated by the investigation of clinical files and pathological reports
of patients. The statistical analysis of survival was performed using the Kaplan-Meier method to
build the survival probability curves. The analysis was carried out through the functions “surv”,
“survfit”, “survdiff”, the log-log mode setting, and “ggsurvplot” from the R packages “survival” and
“survminer”, respectively (ver. 2.42-3, Available online: https://cran.r-project.org/web/packages/
survival/index.html and ver. 0.4.2, Available online: https://cran.r-project.org/web/packages/
survminer/index.html). We used the statistical Log rank test to test the null hypothesis for the
difference of survival curves.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/6/
1559/s1.
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